As of October 27, 2026, Altimmune, Inc. is a publicly traded company (Nasdaq: ALT); its largest reported holder is Deep Track Capital, with 9.99% on Schedule 13G of April 30, 2026, then Chen Yu (9.8%). The largest insider holding is Vipin K. Garg, a director, with 424,519 shares (0.22% of shares outstanding), per Form 4 of February 2, 2026 (Schedule 13G, April 30, 2026).
About to sign with, pay or invest in Altimmune, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Altimmune, Inc. a real, registered company?
- Altimmune, Inc. files with the SEC under CIK 1326190 (its SEC filings).
- Its shares are listed under the ticker ALT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Gaithersburg, Maryland, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Altimmune, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Leadership changes: the latest reported is Richard Menziuso, Vice President, Global Controller and Principal Accounting (Form 8-K filed 2026-09-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-05-12).
Who are Altimmune, Inc.'s owners and officers?
Altimmune, Inc.: incorporated in Delaware; business address in Gaithersburg, Maryland; industry Pharmaceutical Preparations (Form D, 2026-09-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Tang Capital Management, LLC | 0.3% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 5.5% |
| Schedule 13G, 2026-05-01 | Ra Capital Management, L.P. | 6.5% |
| Schedule 13G, 2026-05-01 | Chen Yu | 9.8% |
| Schedule 13G, 2026-05-01 | Viking Global Investors LP | 6.7% |
| Schedule 13G, 2026-04-30 | Deep Track Capital, LP | 9.99% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 9.09% |
| Schedule 13G/A, 2025-07-16 | Blackrock, Inc. | 7.6% |
Want the whole picture on Altimmune, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Altimmune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Altimmune, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-29 | Richard Menziuso | Vice President, Global Controller and Principal Accounting | appointed | 2026-09-29 |
Which insiders own Altimmune, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 424,519 shares (0.22% of shares outstanding) (Form 4, 2026-02-02).
- , the chief scientific officer: 113,699 shares (0.06% of shares outstanding) (Form 4, 2026-08-03).
- , the chief medical officer: 83,874 shares (0.04% of shares outstanding), 16,087 held directly and 67,787 indirectly (Form 4, 2025-08-04).
- , the chief business officer: 70,107 shares (0.04% of shares outstanding) (Form 4, 2026-02-02).
- , the chief executive and president: 62,500 shares (0.03% of shares outstanding) (Form 4, 2026-08-13).
Shares outstanding: 194,517,701 as of 2026-08-07, from the company's latest SEC cover page.
How much has Altimmune, Inc. raised?
No fundraising or offering filing from Altimmune, Inc. is on file with us.
Keep reading
More on Altimmune, Inc. and the records around it.
Altimmune, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026), Inhibrx Biosciences, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 32 other companies: Skye Bioscience, Inc. (Oct 2026), Atea Pharmaceuticals, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/altimmune